S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
New Mexico reaches $500M settlement with Walgreens in opioid case
BREAKING: Tiny biotech successfully treats blindness (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
New Mexico reaches $500M settlement with Walgreens in opioid case
BREAKING: Tiny biotech successfully treats blindness (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
New Mexico reaches $500M settlement with Walgreens in opioid case
BREAKING: Tiny biotech successfully treats blindness (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
New Mexico reaches $500M settlement with Walgreens in opioid case
BREAKING: Tiny biotech successfully treats blindness (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NASDAQ:MEIP

MEI Pharma (MEIP) Price Target & Analyst Ratings

$7.32
+0.01 (+0.14%)
(As of 06/9/2023 ET)
Compare
Today's Range
$7.29
▼
$7.40
50-Day Range
$4.52
▼
$99.36
52-Week Range
$4.00
▼
$13.46
Volume
33,975 shs
Average Volume
77,421 shs
Market Capitalization
$48.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

MEI Pharma Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$40.00
446.45% Upside
High Prediction$40.00
Average Prediction$40.00
Low Prediction$40.00
TypeCurrent
6/10/22 to 6/10/23		1 Month Ago
5/11/22 to 5/11/23		3 Months Ago
3/12/22 to 3/12/23		1 Year Ago
6/10/21 to 6/10/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$40.00$40.00$48.57$102.50
Predicted Upside446.45% Upside515.45% Upside96.11% Upside189.70% Upside
Get MEI Pharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.


MEIP Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MEIP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MEI Pharma Stock vs. The Competition

TypeMEI PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside446.45% Upside1,154.75% Upside247.61% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/24/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Neutral
2/13/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		A. Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy$100.00 ➝ $40.00+599.30%
2/8/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeHold ➝ Underperform
12/6/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
12/6/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
(Data available from 6/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MEIP Price Target - Frequently Asked Questions

What is MEI Pharma's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for MEI Pharma stock is Hold based on the current 1 sell rating, 3 hold ratings and 1 buy rating for MEIP. The average twelve-month price prediction for MEI Pharma is $40.00 with a high price target of $40.00 and a low price target of $40.00. Learn more on MEIP's analyst rating history.

Do Wall Street analysts like MEI Pharma more than its competitors?

Analysts like MEI Pharma less than other Medical companies. The consensus rating for MEI Pharma is Hold while the average consensus rating for medical companies is Buy. Learn more on how MEIP compares to other companies.

Does MEI Pharma's stock price have much upside?

According to analysts, MEI Pharma's stock has a predicted upside of 515.45% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:MEIP) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -